Abstract:
Summary. The prospective 3-months study of the influence of β-erythropoietine (Repretine®) administration on the quality of life in 20 dialyzed patients is described. Treatment dose was 6,000 UI/week. After the treatment hemoglobin levels increased significantly and 70% patients reported the quality of life amelioration. As the physical component of the quality of life index increased from 33,81±1,56 points (M±m) till 38,51±1,49 points (p<0,05) and the psychological component decreased insignificantly from 45,71±6,97 points till 44,77±6,5 points (p>0,05), than composed health index increased due to the amelioration of the physical stage of the patients, that positively correlated with increased hemoglobin values.
Description:
Centrul Dializă şi Transplant Renal IMSP Spitalul Clinic Republican, Catedra Urologie şi Nefrologie Chirurgicală USMF “N. Testemiţanu”, Al V-lea Congres de Urologie, Dializă şi Transplant Renal din Republica Moldova cu participare internaţională (1-13 iunie 2011)
